182 related articles for article (PubMed ID: 34881848)
1. Side effects of theragnostic agents currently employed in clinical practice.
Rizzo A; Annunziata S; Salvatori M
Q J Nucl Med Mol Imaging; 2021 Dec; 65(4):315-326. PubMed ID: 34881848
[TBL] [Abstract][Full Text] [Related]
2. Theragnostic radionuclides: a clinical perspective.
Koziorowski J; Ballinger J
Q J Nucl Med Mol Imaging; 2021 Dec; 65(4):306-314. PubMed ID: 34881851
[TBL] [Abstract][Full Text] [Related]
3. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
4. Nuclear Medicine and Cancer Theragnostics: Basic Concepts.
Zoi V; Giannakopoulou M; Alexiou GA; Bouziotis P; Thalasselis S; Tzakos AG; Fotopoulos A; Papadopoulos AN; Kyritsis AP; Sioka C
Diagnostics (Basel); 2023 Sep; 13(19):. PubMed ID: 37835806
[TBL] [Abstract][Full Text] [Related]
5. Toward the Discovery and Development of PSMA Targeted Inhibitors for Nuclear Medicine Applications.
Pastorino S; Riondato M; Uccelli L; Giovacchini G; Giovannini E; Duce V; Ciarmiello A
Curr Radiopharm; 2020; 13(1):63-79. PubMed ID: 31362683
[TBL] [Abstract][Full Text] [Related]
6. Theragnostic Aspects and Radioimmunotherapy in Pediatric Tumors.
Cimini A; Ricci M; Chiaravalloti A; Filippi L; Schillaci O
Int J Mol Sci; 2020 May; 21(11):. PubMed ID: 32481723
[TBL] [Abstract][Full Text] [Related]
7. Theragnostics in primary and secondary liver tumors: the need for a personalized approach.
Filippi L; Braat AJ
Q J Nucl Med Mol Imaging; 2021 Dec; 65(4):353-370. PubMed ID: 34881847
[TBL] [Abstract][Full Text] [Related]
8. [Therapeutic advances of nuclear medicine in oncology].
Valdés Olmos RA; Hoefnagel CA; Bais E; Boot H; Taal B; de Kraker J; Vote PA
Rev Esp Med Nucl; 2001 Dec; 20(7):547-57. PubMed ID: 11709141
[TBL] [Abstract][Full Text] [Related]
9. Radiopharmaceuticals in the elderly cancer patient: Practical considerations, with a focus on prostate cancer therapy: A position paper from the International Society of Geriatric Oncology Task Force.
Prior JO; Gillessen S; Wirth M; Dale W; Aapro M; Oyen WJG
Eur J Cancer; 2017 May; 77():127-139. PubMed ID: 28391026
[TBL] [Abstract][Full Text] [Related]
10. Paving the way to personalized medicine: production of some promising theragnostic radionuclides at Brookhaven National Laboratory.
Srivastava SC
Semin Nucl Med; 2012 May; 42(3):151-63. PubMed ID: 22475424
[TBL] [Abstract][Full Text] [Related]
11. Theranostic approaches in nuclear medicine: current status and future prospects.
Filippi L; Chiaravalloti A; Schillaci O; Cianni R; Bagni O
Expert Rev Med Devices; 2020 Apr; 17(4):331-343. PubMed ID: 32157920
[No Abstract] [Full Text] [Related]
12. Theragnostic: radiopharmaceuticals and nuclear medicine as viewed through Hegel's eyes.
Boschi S; Castellucci P; Nanni C
Eur J Nucl Med Mol Imaging; 2024 Mar; 51(4):942-946. PubMed ID: 38114617
[No Abstract] [Full Text] [Related]
13. Radiopharmaceuticals for the Diagnosis and Therapy of Neuroendocrine Differentiated Prostate Cancer.
Giovacchini G; Giovannini E; Riondato M; Ciarmiello A
Curr Radiopharm; 2017; 10(1):6-15. PubMed ID: 28034291
[TBL] [Abstract][Full Text] [Related]
14. Theragnostic Radionuclide Pairs for Prostate Cancer Management:
Chhabra A; Thakur ML
Biomedicines; 2022 Nov; 10(11):. PubMed ID: 36359312
[TBL] [Abstract][Full Text] [Related]
15. Imaging-guided targeted radionuclide tumor therapy: From concept to clinical translation.
Sun J; Huangfu Z; Yang J; Wang G; Hu K; Gao M; Zhong Z
Adv Drug Deliv Rev; 2022 Nov; 190():114538. PubMed ID: 36162696
[TBL] [Abstract][Full Text] [Related]
16. [Nuclear medicine in oncotherapy].
Pávics L; Besenyi Z
Magy Onkol; 2015 Sep; 59(3):193-7. PubMed ID: 26339908
[TBL] [Abstract][Full Text] [Related]
17. Economics of New Molecular Targeted Personalized Radiopharmaceuticals.
Cutler CS
Semin Nucl Med; 2019 Sep; 49(5):450-457. PubMed ID: 31470937
[TBL] [Abstract][Full Text] [Related]
18. [Oncology PET radiopharmaceuticals in clinic and research in 2020].
Mikecz P; Fekete A; Tóth G; Környei J; Bali T; Cservenyák T; Borbély K
Magy Onkol; 2020 Jun; 64(2):104-111. PubMed ID: 32520003
[TBL] [Abstract][Full Text] [Related]
19. Targeted therapy in nuclear medicine--current status and future prospects.
Oyen WJ; Bodei L; Giammarile F; Maecke HR; Tennvall J; Luster M; Brans B
Ann Oncol; 2007 Nov; 18(11):1782-92. PubMed ID: 17434893
[TBL] [Abstract][Full Text] [Related]
20. Targeted Radionuclide Therapy: An Evolution Toward Precision Cancer Treatment.
Jadvar H
AJR Am J Roentgenol; 2017 Aug; 209(2):277-288. PubMed ID: 28463538
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
